A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)

K. H. Kim, H. J. Lee, S. J. Lee, M. Kim, M. S. Ahn, M. Y. Choi, N. R. Lee, M. Jung, S. J. Shin

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)S85-S86
JournalEuropean Journal of Cancer
StatePublished - Oct 2022

Cite this